Patents by Inventor Georg Hess

Georg Hess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11047865
    Abstract: Method for determination of whether a subject suffers from intermittent atrial fibrillation based on the determination of the amount of a Troponin T in a sample in a patient suffering from atrial fibrillation using a binding assay. Kits and devices adapted to carry out the methods are also provided.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: June 29, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20210164969
    Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
    Type: Application
    Filed: January 29, 2021
    Publication date: June 3, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Ursula-Henrike Wienhues-Thelen, Dirk Block, Hendrik Heudig, Sabine Vogel-Ziebolz, Christine Boehm, Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Patent number: 11016102
    Abstract: Method for determination of whether a subject suffers from intermittent atrial fibrillation based on the determination of the amount of a Troponin T in a sample in a patient suffering from atrial fibrillation using a binding assay. Kits and devices adapted to carry out the methods are also provided.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: May 25, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Patent number: 10996229
    Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: May 4, 2021
    Assignees: Roche Diagnostics Operations, Inc., The Governing Council of the University of Toronto
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
  • Patent number: 10942175
    Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: March 9, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ursula-Henrike Wienhues-Thelen, Dirk Block, Hendrik Huedig, Sabine Vogel-Ziebolz, Christine Boehm, Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20210032834
    Abstract: The present invention relates to a bucket wheel excavator whose bucket wheel is rotationally drivable and is supported at a pivotable bucket wheel boom and to a method of controlling such a bucket wheel excavator. In accordance with the invention, a mass flow and/or material flow adopted on the removal conveyor after a specific advance on the pivoting of the bucket wheel at the predetermined pivot angle speed is/are determined over the pivot angle, a desired mass flow and/or volume flow is/are specified on the removal conveyor, and then the previously specified pivot angle speed is automatically corrected using the determined mass flow and/or volume flow and the specified desired mass flow and/or volume flow to then perform the pivot cycle at the corrected pivot angle speed of the bucket wheel.
    Type: Application
    Filed: August 21, 2020
    Publication date: February 4, 2021
    Inventors: Klaus GRANER, Phillipp SUHM, Thomas SCHULZE, Georg HESS
  • Publication number: 20200333360
    Abstract: The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 22, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Patent number: 10732188
    Abstract: The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: August 4, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20200064359
    Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 27, 2020
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
  • Patent number: 10488422
    Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: November 26, 2019
    Assignees: Roche Diagnostics Operations, Inc., The Governing Council of the University of Toronto
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
  • Patent number: 10234462
    Abstract: The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: March 19, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Sara Arab, Georg Hess, Hendrik Huedig, Peter Liu, Ursula-Henrike Wienhues-Thelen
  • Publication number: 20180196066
    Abstract: Method for determination of whether a subject suffers from intermittent atrial fibrillation based on the determination of the amount of a Troponin T in a sample in a patient suffering from atrial fibrillation using a binding assay. Kits and devices adapted to carry out the methods are also provided.
    Type: Application
    Filed: March 5, 2018
    Publication date: July 12, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Patent number: 9983213
    Abstract: The present invention relates to a method for identifying a subject being susceptible to anti-angiogenesis therapy based in determining the amount of a cardiac troponin in a sample of the subject and comparing the amount to a suitable reference amount. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: May 29, 2018
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20170261517
    Abstract: The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient.
    Type: Application
    Filed: March 28, 2017
    Publication date: September 14, 2017
    Inventors: Georg HESS, Dietmar ZDUNEK, Andrea HORSCH
  • Patent number: 9638700
    Abstract: The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: May 2, 2017
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Dietmar Zdunek, Andrea Horsch
  • Publication number: 20170082639
    Abstract: Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 23, 2017
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20170023588
    Abstract: Method for determination of whether a subject suffers from intermittent atrial fibrillation based on the determination of the amount of a Troponin T in a sample in a patient suffering from atrial fibrillation using a binding assay. Kits and devices adapted to carry out the methods are also provided.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20170016918
    Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 19, 2017
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
  • Patent number: 9535073
    Abstract: Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: January 3, 2017
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20160146836
    Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker CRYAB, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation, and of assessing heart failure by comparing the concentration determined in for CRYAB and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of CRYAB as a marker protein in the assessment of heart failure, a marker combination comprising CRYAB and a kit for measuring CRYAB.
    Type: Application
    Filed: January 27, 2016
    Publication date: May 26, 2016
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Dirk Block, Hendrik Huedig, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Sara Arab